Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA

CARLSBAD, Calif., June 13, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation and rare pediatric disease designation to ION582, an…

Click here to view original post